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AbstrAct
Objectives There is growing evidence for the role of 
systemic inflammation in Alzheimer’s disease (AD) and 
other neurodegenerative diseases; however the systemic 
inflammatory profile in dementia with Lewy bodies (DLB) 
has never before been investigated. This study aimed 
to characterise systemic inflammatory mediators in 
established DLB and AD, as well as in their prodromal, 
mild cognitive impairment (MCI) phases.
Methods We obtained plasma samples from patients 
with DLB (n=37), AD (n=20), MCI with DLB profile 
(n=38), MCI with AD profile (n=20) and healthy control 
subjects (n=20). The following inflammatory biomarkers 
were measured using Roche cobas c702 and Meso Scale 
Discovery V-Plex Plus: high-sensitivity C-reactive protein, 
interferon-gamma, interleukin (IL)-10, IL-12p70, IL-13, 
IL-1beta, IL-2, IL-4, IL-6, IL-8 and tumour necrosis factor-
alpha.
results We found significantly higher levels of IL-10, 
IL-1beta, IL-4 and IL-2 in both MCI groups (P<0.001), 
while there was no significant difference in inflammatory 
markers between dementia groups and controls. 
Furthermore, increased disease severity was associated 
with lower levels of IL-1beta, IL-2 and IL-4 (P<0.05).
Interpretation We have shown for the first time that 
in both DLB and AD, increased peripheral inflammation 
occurs early at the MCI disease stages. These data 
support a role for inflammation early in the disease 
process, and have important implications for the stage 
of disease where trials of anti-inflammatory medication 
should be focused.
IntrOductIOn
Dementia affects around 50 million people world-
wide, and this is expected to rise to 131.5 million 
by 2050. One of the major problems in dementia 
care is the lack of effective treatments, with current 
pharmacological therapies having limited benefit.
Theories about the role of neuroinflammation in 
the progression of degenerative dementia have been 
gaining interest due to their therapeutic potential. It 
has been suggested that neuronal damage in chronic 
neurodegeneration leads to a damaging proin-
flammatory microglial response.1 In Alzheimer’s 
disease (AD) there has been considerable evidence 
to show that peripheral and central inflammations 
play a key role in the pathogenesis of the disease. 
While serum tumour necrosis factor (TNF)-alpha 
in particular appears to be highly associated with 
cognitive decline,2 associations have been made 
with several other systemic inflammatory markers.3 
Longitudinal studies have found that inflammation 
occurs years before AD onset,4 5 and cross-sectional 
studies have found a large increase in inflammatory 
markers in the mild stages of disease.6 Further-
more, genome-wide association studies (GWAS) 
have identified several risk AD candidate genes 
for inflammatory pathways, which are strongly 
supportive of inflammation playing a critical role in 
early AD aetiology.7
Dementia with Lewy bodies (DLB) is the second 
most common cause of degenerative dementia, 
and shares many clinical characteristics with AD. A 
recent meta-analysis showed that there is increased 
systemic inflammation in patients with Parkin-
son’s disease, which is closely related to DLB.8 It 
is therefore likely that the neuroinflammatory 
processes occurring in AD are also involved in 
driving neurodegeneration in DLB, with cytokines 
such as interleukin (IL)-1 being implicated in the 
neuropathological changes characteristic of both 
conditions.9
Only two studies have assessed inflammation in 
patients with DLB, both using cerebrospinal fluid 
(CSF), with one finding lower levels of IL-6 and 
the other finding no significant difference.10 11 No 
studies have examined inflammatory markers in the 
blood compared with controls, although a small 
exploratory study found that increased peripheral 
levels of IL-6 were associated with cognitive impair-
ment in patients with DLB.12 The accessibility and 
practicality of using peripheral blood to monitor 
neuroinflammation in patients make this an attrac-
tive option. Furthermore, the increasing evidence 
that peripheral inflammation and neuroinflamma-
tion are closely related suggests that altered systemic 
inflammatory markers reflect neurodegenerative 
disease.13 Therefore, there is a need to investigate 
systemic inflammatory markers in patients with 
DLB as markers of brain inflammation.
The aim of this study was to characterise the 
plasma cytokine profile and C-reactive protein 
(CRP) levels of patients with DLB and compare 
this with patients with AD and healthy control 
subjects. Furthermore, we aimed to compare this 
with patients with mild cognitive impairment 
(MCI) thought to be due to AD and DLB to assess 
inflammation at this earlier pre-dementia stage. 
We hypothesised that the inflammatory profile in 
patients with DLB would be similar to that seen in 
patients with AD, and would be raised compared 
with healthy control subjects. Furthermore, we 
hypothesised that patients with MCI would have 
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raised inflammatory markers compared with healthy control 
subjects and patients with dementia.
MethOds
subjects
Patients with dementia and MCI were recruited from the same 
memory clinics and dementia services including neurology and 
geriatrics in the North-East of England. All patients were aged 
over 60 and had provided written informed consent, or in cases 
where capacity was lacking their participation in the study was 
discussed with a consultee in accordance with UK legislation.
Patients with dementia had a Mini Mental State Examination 
(MMSE) score of at least 12. Diagnosis of DLB was made based 
on the International Consensus criteria,14 and patients with AD 
were diagnosed based on the National Institute of Neurological 
and Communicative Disorders and Stroke and the Alzheimer’s 
Disease and Related Disorders Association criteria.15 16 Patients 
with MCI met the National Institute on Aging and Alzheimer’s 
Association MCI criteria.16 Probable Lewy Body MCI (MCI-LB) 
was diagnosed using the Diagnostic and Statistical Manual of 
Mental Disorders 5 criteria,17 with the inclusion of dopami-
nergic imaging so that probable MCI-LB was diagnosed when 
at least two core or suggestive features of DLB were present, 
but in the absence of dementia. If none of these symptoms were 
present, the patient was classified as MCI-AD. Dementia and 
MCI diagnoses were made by a consensus panel of three expe-
rienced clinicians. Healthy control subjects were recruited from 
patients’ friends or family, or people who had already indicated 
a willingness to participate in research.
We further classified participants as having amnestic subtype if 
their Rey delay score was less than 3 and as non-amnestic if their 
Rey delay score was 3 or more in order to ascertain whether 
there was any difference in inflammation.
Exclusion criteria included severe physical, neurological or 
psychiatric illness, history of alcohol excess, and use of psycho-
tropic drugs. We also excluded people who had a history or 
evidence of a stroke and those with possible or probable vascular 
dementia. We did not exclude people with inflammatory or 
autoimmune diseases; however, information regarding this was 
collected and taken into account during analysis.
Assessments
All patients were assessed by the equivalent of a board-certified 
medical practitioner, including a physical and neurological exam-
ination, and assessment of parkinsonism used the Movement 
Disorder Society Unified Parkinson’s Disease Rating Scale Part 
III (UPDRS). They were free from acute inflammatory illness, 
and their illness burden was assessed using the Cumulative Illness 
Rating Scale-Geriatrics (CIRS-G). Cognition was assessed using 
the Addenbrooke’s Cognitive Examination Revised (ACE-R) and 
MMSE.
Psychiatric symptoms were assessed using the Neuropsychiatric 
Inventory and the Geriatric Depression Scale. Activities of daily 
living were assessed using the Instrumental Activities of Daily 
Living Scale and Bristol Activities of Daily Living Scale. Doses 
of levodopa and antidementia medications were documented. 
Based on these assessments, healthy control subjects did not show 
any evidence of dementia. Positron emission tomography (PET) 
imaging was carried out on all dementia and healthy comparison 
subjects to investigate the amyloid burden in the brain.
Measurement of cytokines and high-sensitivity crP
Venous blood samples were taken from all subjects using EDTA 
tubes, which were then centrifuged and the plasma removed. 
Samples were stored at −80° until assays were performed. Cyto-
kine assays were performed using the Meso Scale Discovery 
V-Plex Plus Proinflammatory Panel 1, which included inter-
feron (IFN)-gamma, IL-1beta, IL-2, IL-4, IL-6, IL-8, IL-10, 
IL-12p70, IL-13 and TNF-alpha. Assays were analysed at the 
National Institute for Health and Research-Newcastle University 
Biomarkers Facility according to the manufacturer’s protocol, 
and samples were processed in triplicates. Samples that were 
under the limit of detection for a particular cytokine (<0.05 for 
IFN-gamma, <0.03 for IL-13, <0.02 for IL-12p70 and <0.01 
for all other cytokines) had cytokine levels that were low enough 
to be undistinguishable from background noise, and therefore 
these samples were treated as having ‘zero’ levels of that cyto-
kine. High-sensitivity CRP (hsCRP) was analysed using Roche 
cobas c702, and was carried out at the Royal Victoria Infirmary 
in Newcastle upon Tyne.
Analysis
Statistical analysis was completed using IBM SPSS Statistics 
V.23 software (http:// www- 03. ibm. com/ software/ products/ en/ 
spss- statistics). Data distribution and normality were assessed 
using the Shapiro-Wilk test, and log transformations were 
performed to attempt to normalise any skewed data. Compar-
isons between diagnostic groups were carried out using analysis 
of variance or Kruskal-Wallis tests depending on normality of the 
data following log transformations. Where gender differences 
between groups were present, gender was added as a covariant 
in the analysis. Bonferroni correction was used to correct for 
multiple comparisons, so that P<0.001 was required for signifi-
cance. Correlations were sought between inflammatory markers 
and patient characteristics using Spearman’s rank correlation, 
due to some of the data not being normally distributed following 
log transformation. Finally, significant differences in cytokine 
levels were sought between participants with amyloid-positive 
and amyloid-negative PET scans, and between participants with 
amnestic and non-amnestic subtype.
results
One hundred and thirty-six subjects took part in this study. 
Of these, 20 were healthy control subjects, 20 with AD, 37 
with DLB, 38 with MCI-LB and 21 with MCI-AD (see table 1 
for full details of subject characteristics). The mean age of the 
whole cohort was 76.2 (±6.9) years, and this was not signifi-
cantly different between any of the groups. In all groups except 
the MCI-AD group, there were more men than women. Disease 
duration was around 2 years in both the DLB and AD patients. 
As expected, UPDRS was higher in the DLB groups compared 
with all other groups, the ACE-R and MMSE scores were lower 
in the dementia and MCI groups compared with healthy control 
subjects, and a higher proportion of patients with dementia were 
taking anti-dementia medications than patients with MCI. The 
proportion of patients taking anti-inflammatory medications 
ranged between 25% and 66%, but in the majority of cases this 
was low-dose aspirin (75 mg), prescribed for its vascular effects. 
Eight participants were taking a non-aspirin non-steroidal 
anti-inflammatory drug, and seven were taking a steroid; these 
were spread evenly between all groups.
The CIRS-G identified that the DLB group had a signifi-
cantly higher general medical illness score than other groups. 
However, this was due to the DLB group scoring more highly 
in the neurological and psychiatric aspects of the assess-
ment, as would be expected by the increased incidence of 
parkinsonism and hallucinations in these groups of patients. 
Once these neurological and psychological aspects had been 
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removed from analysis, there were no significant differences 
between any of the groups (see table 1).
We also looked specifically at the prevalence of autoimmune 
comorbidities in each group due to the impact it can have on 
inflammation. Overall one control participant had rheumatoid 
arthritis, one or two participants in each group had hypo-
thyroidism or hyperthyroidism, one control participant had 
giant cell arteritis, two patients with DLB had polymyalgia, 
one patient with DLB and one patient with MCI-LB had gout, 
and one control participant had ‘immune system disease’ not 
otherwise specified. Therefore the prevalence of autoimmune 
inflammatory disease was spread evenly across groups. Overall 
all other comorbidities including vascular comorbidities were 
spread evenly between groups.
Inflammatory marker levels
Table 2 shows all cytokine and hsCRP results. Overall, patients 
in both MCI groups had significantly higher levels of IL-10, 
IL-1beta, IL-4 and IL-2 than control, AD or DLB groups. Both 
MCI groups had lower levels of TNF-alpha than the control or 
dementia groups. IL-13 was removed because more than 50% 
of the samples had non-detectable cytokine levels. Furthermore, 
IL-12p70 was removed due to the high interassay variability. 
There were no significant differences between either of the 
dementia groups and control subjects, and there were no signif-
icant differences between the two dementia groups or between 
the two MCI groups (table 2). Cohen’s effect sizes were calcu-
lated and were large (d>0.8) for all significant differences, apart 
from that between the AD group and MCI groups for IL-10, 
table 1 Differential diagnosis for decreased conscious level
controls (n=20) dlb (n=37) Ad (n=20) McI-lb (n=38) McI-Ad (n=21)
Age (years±SD) 75.9±7.3 76.1±6.6 75.9±6.7 75.6±7.5 78.5±6.4
Sex (M:F) 16:4 30:7§ 15:5 25:13 7:14*
Disease duration (months±SD) 25.2±20.4 24.2±20.9
MMSE (score±SD) 29.1±0.9*†‡§ 21.2±4.6‡§¶ 20.3±4.7‡§¶ 26.4±2.3*†¶ 26.5±2.1*†¶
ACE (score±SD) 94.8±3.0*†‡§ 62.1±15.4‡§¶ 60.5±16.5‡§¶ 78.2±9.6*†¶ 79.4±11.1*†¶
UPDRS (score±SD) 5.6±3.5*†‡§ 43.0±18.1†‡§¶ 13.6±7.2*‡¶ 27.2±16.2*†§¶ 15.7±6.5*‡¶
NPI (score±SD) 20.4±19.9§ 14.0±13.3§ 14.3±10.5§ 5.1±6.2*†‡
Levodopa use (no of patients, %) 0 (0%) 13 (35%) 0 (0%) 8 (21%) 0 (0%)
Antidementia medication (no of 
patients, %)
– 35 (96%)‡§ 20 (100%)‡§ 18 (47%)*† 5 (24%)*†
Anti-inflammatory medication (no of 
patients, %)
13 (65%) 14 (38%) 5 (25%) 23 (66%) 9 (43%)
CIRS-G (score±SD) 6.7±4.3* 11.5±4.1¶ 8.6±3.6 9.5±4.3 9.5±3.9
CIRS-G without neuro/
psych (score±SD)
6.5±4.1 8.1±3.8 6.2±3.4 8.4±4.5 8.2±4.4
Results are presented as mean and SD.
Antidementia medication includes donepezil, rivastigmine, galantamine and memantine. Anti-inflammatory medication includes all non-steroidal anti-inflammatory drugs and 
steroids.
*Significantly different from DLB group (P<0.05).
†Significantly different from AD group (P<0.05)
‡Significantly different from MCI-LB group (P<0.05)
§Significantly different from MCI-AD group (P<0.05)
¶Significantly different from controls (P<0.05).
ACE, Addenbrooke’s Cognitive Examination; AD, Alzheimer’s Disease; CIRS-G, Cumulative Illness Rating Scale-Geriatric; CIRS-G without neuro/psych, CIRS-G score without the 
neurology or psychiatric components included; DLB, dementia with Lewy bodies; MCI, mild cognitive impairment; MCI-AD, MCI with probable Alzheimer’s disease; MCI-LB, MCI 
with probable Lewy body dementia; MMSE, Mini Mental State Examination; NPI, Neuropsychiatric Inventory; UPDRS, Unified Parkinson’s Disease Rating Scale. 
table 2 Level of inflammatory markers in patients and controls
control dlb Ad McI-lb McI-Ad
CRP, mg/mL 3.35±5.72 1.73±2.12 6.29±14.56 4.12±6.44 3.41±3.34
IFN-gamma, pg/L 7.56±6.13 5.13±4.13 9.01±12.06 6.52±4.30 8.75±12.08
IL-10, pg/L 0.46±0.62 0.43±0.52 0.60±0.75 0.96±0.54*†‡ 0.93±0.36*†‡
IL-1beta, pg/L 0.51±2.16 0.07±0.33 0.03±0.08 1.92±1.24*†‡ 2.72±1.51*†‡
IL-2, pg/L 0.38±0.42 0.34±0.37 0.39±0.68 3.68±0.85*†‡ 3.56±0.92*†‡
IL-4, pg/L 0.03±0.05 0.02±0.03 0.01±0.03 0.80±0.16*†‡ 0.85±0.21*†‡
IL-6, pg/l 1.66±0.99 2.02±2.00 2.78±2.21 2.90±10.39 3.32±4.34
IL-8, pg/L 4.85±1.49 5.10±2.03 5.11±2.25 6.75±17.50 4.34±2.88
TNF-alpha, pg/L 4.26±1.32 4.02±1.61 4.28±2.38 2.23±2.01*†‡ 3.08±3.53*†
Results are presented as mean±SD.
*Significantly different from controls (P≤0.001). 
†Significantly different from DLB group (P≤0.001). 
‡Significantly different from AD group (P≤0.001). 
AD, Alzheimer’s disease; CRP, C reactive protein; DLB, dementia with Lewy bodies; IFN-gamma, interferon-gamma; IL, interleukin; MCI, mild cognitive impairment; MCI-AD, MCI 
with probable Alzheimer’s disease; MCI-LB, MCI with probable Lewy body dementia; TNF-alpha, tumour necrosis factor-alpha. 
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which were moderate (d=0.55 and d=0.56 for AD vs MCI-LB 
and AD vs MCI-AD respectively). The median values for intra-
assay and interassay coefficient of variance across all cytokines 
were 9.87% and 16.04%, respectively. Correction calculations 
were carried out based on the values obtained for internal 
controls to account for this variation. There were no significant 
differences in hsCRP level between any of the groups (table 2).
correlations
Spearman’s rank correlation was used to explore any correla-
tions between inflammatory markers and patient characteristics. 
Healthy control subjects were excluded from the correlation 
analysis. Increasing age was correlated with a higher level of 
IFN-gamma. Greater severity of cognitive impairment measured 
using the ACE-R and the MMSE was associated with having a 
significantly lower level of IL-1beta, IL-2 and IL-4, and a higher 
level of IL-6 and TNF-alpha (figure 1).
Correlations were also sought between the level of parkin-
sonism and inflammatory markers using the UPDRS. AD groups 
were also removed from this analysis, as parkinsonism is not a 
feature in this group and scores were consequently low. Overall, 
a significantly higher score on the UPDRS was associated with 
having lower levels of IL-1beta, IL-2 and IL-4, and a higher level 
of IL-6 and TNF-alpha.
When looking at the MCI and dementia groups separately, a 
greater level of parkinsonism was associated with a lower level of 
IL-1beta and IL-4 in the MCI-LB group only. In the DLB group, 
the only significant correlation was between having more severe 
parkinsonian symptoms and a higher level of IL-10.
Inflammatory markers and amyloid
There were no significant differences in any of the cytokine levels 
between participants with amyloid-positive and amyloid-nega-
tive PET scans.
Figure 1 Correlations between Unified Parkinson’s Disease Rating Scale (UPDRS) and Addenbrooke’s Cognitive examination (ACe) scores with cytokine 
levels. (A,B) Correlations between UPDRS and interleukin (IL)-1beta (r=−0.285, P=0.002), IL-2 (r=−0.220, P=0.018) and IL-4 (r=−0.217, P=0.019), and 
between UPDRS and IL-6 (r=0.208, P=0.025) and tumour necrosis factor (TNF)-alpha (r=0.168, P=0.071). (C,D) Correlations between the ACe score and 
IL-1beta (r=0.494, P=0.000), IL-2 (r=0.485, P=0.000) and IL-4 (r=0.540, P=0.000), and between the ACe and IL-6 (r=−0.343, P=0.000) and TNF-alpha 
(r=−0.253, P=0.006).
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Inflammatory marker in amnesic versus non-amnesic patients
There were no significant differences in any of the cytokine 
levels between participants with amnestic and non-amnestic 
MCI subtype.
dIscussIOn
We investigated for the first time the peripheral cytokine profile 
in DLB and AD both at the MCI stage and at the dementia 
stage, and compared with healthy control subjects. We found 
that while there was no difference in the level of inflamma-
tory markers between control and dementia subjects, there 
was a significant increase in inflammatory markers at the MCI 
stage. Specifically, we found significantly higher levels of IL-10, 
IL-1beta, IL-4 and IL-2 in both MCI-LB and MCI-AD compared 
with dementia and control subjects. Furthermore, greater disease 
severity, whether measured for cognition or parkinsonism, was 
associated with lower levels of IL-1beta, IL-2 and IL-4, further 
supporting our finding that inflammatory markers decrease with 
disease progression. To our knowledge this is the first study to 
investigate baseline inflammatory markers in DLB with control 
subjects, and we found that peripheral inflammation in DLB 
shows a similar pattern to that seen in AD.
The results from this study are consistent with previous 
studies of AD. Previous studies have demonstrated lower levels 
of IL-1beta, Il-6, IL-12, IL-16, IL-18 and TGF-β1 in severe AD 
compared with mild or moderate disease.6 18 CSF chemokine 
levels have also been found to be increased in MCI compared 
with patients with AD.19 Peripheral blood mononuclear cell stim-
ulation studies have found similar patterns of immune dysfunc-
tion; one study found higher levels of cytokine production in 
patients with MCI than AD or controls,20 and another found 
significantly lower levels of cytokine release in severe AD.18 21 
A recent meta-analysis found that increased peripheral levels 
of inflammatory markers are associated with an increased risk 
of later dementia, indicating that peripheral inflammation may 
occur before clinical symptoms are present.22
Few studies have investigated inflammatory markers in DLB. 
One study found that IL-6 in CSF was negatively correlated with 
MMSE,11 and a correlation study found that increasing IL-6 is 
associated with cognitive decline.12 In our study IL-6 was one of 
the only cytokines that were negatively correlated with cognitive 
function, and it was also correlated with worsening parkinsonian 
symptoms. However, studies investigating Parkinson’s disease 
suggest that high IL-6 levels increase the risk of later Parkin-
son’s disease, implying that high IL-6 may be associated with 
triggering disease onset.23 These findings suggest that IL-6 may 
show a more complex relationship with disease progression, 
perhaps increasing both early and late in disease.
The only cytokine that we found to be decreased in patients 
with MCI was TNF-alpha, which was also associated with wors-
ening cognition and parkinsonism. Previous studies investigating 
TNF-alpha in AD have found mixed results. While some studies 
have found increased levels of TNF-alpha in patients with 
AD,24 25 some have found decreased levels26 27 and others have 
found no difference.28 Studies investigating TNF-alpha levels at 
different stages of disease have in general found higher levels 
of TNF-alpha in patients with severe AD compared with mild 
AD and MCI,29 30 and therefore it may be that the increase in 
TNF-alpha is seen at a later stage in disease than other cytokines.
The underlying cause for this inflammation seen early 
in disease is still not fully understood, although it has been 
suggested that in the early stages of disease, aberrant protein 
deposition induces a microglial inflammatory response in 
the brain, leading to peripheral inflammation.31 It has been 
suggested that it is this initial microglial activation that produces 
toxic products, producing further neuronal death and thereby 
perpetuating the inflammatory reaction.32 Previously, studies 
have also found increased inflammation peripherally in Parkin-
son’s disease,8 33 suggesting that inflammation may indeed be 
associated with aberrant protein aggregation and not specifically 
beta amyloid (Aβ). However studies investigating inflammation 
in Parkinson’s disease dementia have found mixed results,34 35 
which could perhaps be a reflection of the severity of disease of 
this cohort of participants, with such patients being less likely to 
be in the early stages of disease.
Although it is not clear how systemic inflammation relates to 
disease processes occurring in the brain, studies suggest that periph-
eral inflammation and central inflammation are closely related.2 
Microglia expressing IL-1 appear to be more highly associated 
with early-stage than late-stage Aβ plaques in AD brains, and IL-1 
may be important in driving plaque progression.36 Furthermore, 
administration of Aβ centrally in mice induces a dose-dependent 
increase in peripheral IL-6,37 suggesting that there is some rela-
tionship between peripheral inflammatory markers and central 
disease progression. It has been suggested that Aβ deposition 
may drive cognitive decline in people with AD, DLB and PD, 
perhaps by inducing inflammation; however, evidence is limited 
and results are inconsistent.38 The present study found no rela-
tionship between Aβ and inflammatory marker levels, suggesting 
that inflammation may not be a direct consequence of Aβ depo-
sition. A previous study showed that inflammation appears to be 
a better marker for synapse loss seen in AD than Aβ deposition, 
suggesting that there is a role for inflammation driving neuro-
degeneration.39 This study suggests that while there is a clear 
increase in inflammation at the MCI stage, there appears to be 
an imbalance between proinflammatory and anti-inflammatory 
cytokines, something that is thought to be highly important in the 
progression from acute inflammation to chronic disease.40
This study did not investigate patients with severe dementia; 
however, the correlation analysis suggests that as disease 
progresses, the level of inflammation decreases. Previous studies 
investigating this have indeed shown that there appears to be 
a gradual decrease in the level of inflammatory markers with 
disease progression, reaching levels below healthy in severe 
disease.6 18 However, although chronic inflammation appears to 
decrease with disease severity, acute inflammation still likely has 
an impact on the rate of decline, as it has been shown that acute 
increases in TNF-alpha in patients with dementia predict more 
rapid disease progression.2
This decrease in chronic inflammation seen later in disease may 
relate to the chronic neurodegenerative processes involved in 
dementia progression. It has been shown in transgenic mice that 
chronic Aβ exposure in the brain is associated with a decreased 
immune response.41 It may be that chronic exposure to Aβ in AD 
leads to increased tolerance for Aβ deposition. This may result 
in immune hyporesponsiveness, which may contribute towards 
further Aβ deposition. It seems likely that a similar inflammatory 
process is occurring in DLB; however, more evidence is needed 
to ascertain whether this is also related to beta deposition, or 
whether this is as a result of alpha-synuclein. Therefore, it could 
be hypothesised that while aberrant protein deposition in the 
brain in AD and DLB may initially trigger an immune response 
leading to an increase in inflammatory markers and therefore 
neuronal toxicity, chronic exposure may lead to tolerance and a 
hyporesponsive immune system.
These findings have important implications for the manage-
ment of dementia. Previous studies have investigated the use 
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of anti-inflammatory medication in the treatment of AD and 
found no clinical benefit.42 However, because the patients 
in these cohorts had already progressed from MCI to AD, 
it is likely that the stage of dementia was too advanced for 
the anti-inflammatory medication to have had any clinical 
benefit. Observational studies have found that long-term use 
of anti-inflammatory medications is associated with a reduced 
risk of dementia, indicating that the beneficial effects of 
anti-inflammatory medications may only apply in very early 
stages of disease.43 Further studies are needed to ascertain the 
optimum time, dose and type of anti-inflammatory medication 
to be used in the management of patients with MCI. More 
recent studies have suggested that there may be a role for 
more specific anti-inflammatory agents; a pilot study found 
improvements in cognition in patients with AD taking specific 
TNF-alpha inhibitors.44 Randomised controlled trials are 
needed to ascertain the benefit of anti-inflammatory antibody 
therapies in AD and DLB.
Strengths of this study include the large patient group used 
and the thorough clinical assessment of each patient by an expe-
rienced clinician using detailed rating scales. Robust exclusion 
criteria were used, including routine blood tests to assess for 
systemic disease. Limitations include the cross-sectional design 
of the study, the high number of samples falling below the 
detection level for IL-13 leading to exclusion of IL-13, and the 
severity of the dementia groups, having excluded patients with 
an MMSE score of less than 12.
In conclusion, we have shown for the first time that in 
both AD and DLB, increased peripheral inflammation occurs 
early at the MCI stage and decreases with severity of disease. 
It seems likely therefore that there is an early microglial 
response to aberrant protein deposition, which progresses to 
an immune tolerance in chronic disease leading to immune 
hyporesponsiveness. Early treatment of AD and DLB at the 
MCI stage with anti-inflammatory medication may therefore 
be of benefit, and our results indicate that further trials should 
focus on early-stage disease.
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